Tarsus Pharmaceuticals, an Irvine, Calif.-based clinical-stage biopharmaceutical company, closed a $60m in Series B financing.
The round was led by Vivo Capital and included Frazier Healthcare Partners, Flying L Partners, Visionary Ventures, Aperture Venture Partners, and Horowitz Group.
The company will use the funds to initiate a Phase 2b/3 trial in the U.S. of their lead product TP-03 for Demodex blepharitis and fuel Phase 1 and 2 development of other clinical programs.
Led by Bobby Azamian, MD, PhD, CEO, Tarsus is a clinical-stage biopharmaceutical company founded to bring innovative therapies to a range of diseases in need of better solutions, starting with Demodex blepharitis and eye care.
The company’s product pipeline includes additional indications in eye care and other areas of high unmet clinical need. | To read full story, visit https://startuparound.com/read/1578495610.4828422/Tarsus-Pharmaceuticals-Secures-$60M-in-Series-B-Financing?ref=audio_experience